Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews

Liquid Biopsy: From Isolation to Downstream Applications 2018
Jun.2018

liquid_biopsy_market_ecosystem_for_2017_2018_yole
6 490 €

Choose a minimum of three reports from Yole Group and receive a discount of at least 36% on your package – Contact us!
+

Description

couv flyer liquidHow will liquid biopsy change cancer care?

LIQUID BIOPSY: A POWERFUL EMERGING TOOL FOR CANCER CARE, AND A HUGE BUSINESS OPPORTUNITY

Cancer is a rising concern in modern society. Numerous drivers contribute to the increase of cancer cases, such as ageing of the population, lifestyle, and environment. According to the World Health Organization, cancer is responsible for one in six deaths worldwide, and one in two people are likely to develop cancer in their lifetime. Cancer cells are cells whose genes have mutated; in order to understand each cancer’s mechanisms and determine the appropriate treatment, these tumors require analysis. Traditional biopsy methods involve obtaining a piece of the tumor through invasive surgery. However, these procedures are expensive and exhausting for the patient, and cannot be reproduced regularly in order to monitor a cancer’s evolution and treatment efficiency over time. However, it is now possible to avoid such invasive procedures thanks to a “liquid biopsy”. Indeed, it is possible to collect a simple blood draw in which relevant biomarkers can provide useful information about the patient’s cancer. In particular, a number of companies are developing technologies to collect, isolate, and analyze circulating tumor DNA (ctDNA: DNA molecules shed by cancerous cells) and circulating tumor cells (CTCs: tumor cells shed from the original tumor) that spread into the bloodstream. Thanks to these tools, it is possible to not only diagnose cancer uninvasively, but also to understand the molecular mechanisms associated with each patient, choose and develop a tailored treatment, monitor the treatment’s efficiency (along with drug resistance), and screen for disease recurrence. Some companies are even working on screening for early detection, although this is a more long-term application.

Liquid biopsy thus has the potential to assist at every stage of cancer care, saving lives and cutting healthcare costs. The opportunity is huge, and the associated market is already large and growing extremely fast. According to this Yole Développement report, the liquid biopsy market will grow from $1.7B in 2017 at a CAGR2017-2023 of 29%, reaching $7.8B by 2023. This includes hardware (systems and devices) and reagent kit sales, along with service revenue, for CTC and ctDNA applications.

 Liquid biopsy a game changer in cancer care 2018 Yole

AN IMPRESSIVE RANGE OF COMPANIES AND BUSINESS MODELS

Studying mutations in cancer cells’ DNA is not an easy task, and requires many different tools and skills. From the enrichment and analysis of biomarkers to the bioinformatics analysis of mutation profiles, the path is long and many players are involved. This report confirms the role of each player at each level of the supply chain, explains who is specialized in which step, and details where the value lies and how the development of liquid biopsy is boosting downstream analysis equipment markets like sequencing and digital PCR. The difference and complementarity of ctDNA and CTCs is also described, and Yole Développement’s analysts explain why CTC has yet to attract significant funding, and how the situation may now change thanks to recent findings.

Indeed, ctDNA companies have raised more than $3.7B since 2010, while CTC companies have only raised around $280M. In terms of revenue, the split is also unbalanced in favor of ctDNA companies. This is primarily due to business models: most ctDNA companies offer testing services in their Clinical Laboratory Improvement Amendments (CLIA) labs, performing tests developed in-house which do not require Food and Drug Administration (FDA) clearance. Moreover, DNA is easier to transport and store than live cells, which is another advantage for ctDNA. On the contrary, most CTC companies are developing instruments that are directly sold to endusers, along with the associated consumables.

However, most of these instruments for CTC isolation are still for research use only because the FDA requires more evidence of the benefits derived from analyzing CTCs in patients’ survival rate, before approving them for clinical use. This explains, at least partially, why CTC companies are lagging behind in terms of revenue. Thankfully, this situation may soon change thanks to advances in technology and to the increasing number of published works proving the clinical value of CTC analysis: in fact, a complete live cell can carry much more information than a DNA strand.

 2017 2013 MEMS market forectasts RF 2018 Yole i micronews

TECHNOLOGICAL BREAKTHROUGHS ARE DRIVEN BY MICROFLUIDIC TECHNOLOGY

Many steps in the liquid biopsy workflow have been made possible thanks to microfluidic technologies. From isolation to downstream analysis, microfluidic devices are involved everywhere. A major part of CTC enrichment and isolation systems relies on microfluidic devices that enable separation of CTCs from other blood cells, using their physical properties such as size, shape, deformability, and dielectric properties. Important companies such as Angle plc, Celsee, Clearbridge Biomedics, and Vortex Biosciences rely on microfluidics. These microfluidic methods work for a wide range of cells and enable high throughput capture at a low cost. Moreover, downstream analysis solutions also rely on microfluidic technologies in numerous cases: DNA sequencers from Illumina, Ion Torrent, and others use microfluidic flow cells, and other technologies like droplet digital PCR from Bio- Rad, Stilla Technologies, and RainDance (acquired by Bio-Rad) are also microfluidic technologies.

All of these state-of-the-art technologies are enabled by innovative microfluidic hardware and allow more complex analyses to be performed, thus contributing to concrete improvements in cancer care. In this report, Yole Développement focuses on these microfluidic technologies at every level of the liquid biopsy workflow.

 

Detecting to global perception awareness 2018 Yole i micronews

OBJECTIVES OF THE REPORT

  • Explain what liquid biopsy is, why it is used, and the characteristics of each biomarker (ctDNA,CTC, exosomes)
  • Show what constitutes “state-of-the-art” is today and what is expected for tomorrow, and understand the positive and negative impacts on the adoption of liquid biopsy for clinical use
  • Provide a players overview at each supply chain level, from enrichment and isolation to downstream analysis, for CTC and ctDNA applications
  • Provide a list and analysis of fundraisings and M&A
  • Provide an analysis of the business models used in the liquid biopsy fiel

 

 

Table of contents

Executive summary 9


 

Introduction 50


> What is liquid biopsy?
> What can we learn from Liquid Biopsy?
> Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)
> Report scope

 

 

Liquid biopsy market analysis 64


> Applications and drivers
> Cancer prevalence
> Liquid biopsy ecosystem
> Mergers and acquisitions/collaborations
> Fundraising analysis
> Market data and forecasts 2017 - 2023
> Business models
> Regulations status
> Roadmaps

 

 

Circulating tumor DNA and exosomes 89


> Introduction to ctDNA and exosome technologies in liquid biopsy
> Workflow for detection of ctDNA and exosomes in cancer patients 
> Main players and market share
> Market data and forecasts 2017 – 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   

> Supply chain analysis
> Company profiles

 

 

Circulating Tumor Cell 132


> Introduction to CTCs
> CTCs - analysis workflows in liquid biopsy
> CTCs - enrichments and isolation methods
> Workflow coverage for the main CTC players
> Main players and players map
> Market data and forecasts 2017 – 2023
> Supply chain analysis
> Company profiles

 

 

Downstream analysis 184


> Overview of analytical approaches for liquid biopsy
> Main technologies and requirements
> Focus on next-generation sequencing: main players and applications
> Focus on polymerase chain reaction and beaming technology - main players and applications
> Company profiles

 

 

General conclusions 208


 

Companies cited

Abbott
AdnaGen
Agilent Technologies
Amazon
Amgen
Angle
ApoCell
Assurex Health
AstraZeneca
Axon Dx
BD
Beckman Coulter
BGI
Biocartis
Biocept
Biodesix
BioFluidica
Bio-Rad
Bioview
Bristol Myers Squibb
Cambridge Consultants
CellMax Life
CellSearch
Celsee
Circulogix
Cirina
Clearbridge BioMedics
Clinical Genomics
Cogent
Creativ MicroTech
Cynvenio
CytoLumina
CytoTrack
DiaDx
Diagnologix
Epic Sciences
Epigenomics
Exact Sciences
ExosomeDx
FivePrime
Fluxion
Foundation Medicine
Freenome
GE Healthcare
Genapsys
Gendia
Genomic Health
Gilupi
GnuBio
Grail
Greiner Bio-One
Guardant Health
HP
IBM Watson
iCellate
IKOTECH

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Illumina
IncellDx
Inivata
Janssen Pharmaceuticals
Johnson & Johnson
Life Technologies
LifeArc
Livzon
Menarini Silicon Biosystems
Merck
Microsoft
Mikro Biyosistemler
Miltenyi Biotec
Myriad
Nabsys
Nanostring
Natera
Noblegen
Novartis
Oncocyte
Oxford Nanopore
Pacific Biosciences
Pathway Genomics
Personal Genome Diagnostics
Pfizer
Predicine
Qiagen
RareCells
Roche
SBI
ScreenCell
Sigma Aldrich
Simfo
Sividon Diagnostics
SRI Biosciences
StemCell Technologies
Stratec
Streck
Sysmex
TeloVision
Thermo Fisher
Thermo Fisher Scientific
ThinXXS
Trovagene
Veracyte
Vitatex
Vortex Biosciences
Zomedica
and many more.

KEY FEATURES OF THE REPORT

  • Introduction to liquid biopsy testing, definitions, and why it is used
  • Market analysis of mergers and acquisitions, collaborations, fundraisings and business models
  • Technical and biological requirements, product examples, key players, market share, and technology trends
  • Market overview and forecasts at both service and device levels, for circulating tumor DNA (ctDNA: DNA molecules shed by cancerous cells) and for circulating tumor cells (CTCs: tumor cells shed from the original tumor) applications
  • Overview of the market’s main players and the technologies involved, including company profiles
  • Focus on downstream analysis and identification of the main technologies used for liquid biopsy
  • Supply chain analysis